Compare HQY & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HQY | HALO |
|---|---|---|
| Founded | 2002 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 8.8B |
| IPO Year | 2014 | N/A |
| Metric | HQY | HALO |
|---|---|---|
| Price | $73.19 | $77.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 12 |
| Target Price | ★ $118.40 | $76.42 |
| AVG Volume (30 Days) | 1.1M | ★ 1.9M |
| Earning Date | 03-17-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.97 | 56.68 |
| EPS | 2.18 | ★ 4.74 |
| Revenue | ★ $1,290,660,000.00 | $1,242,852,000.00 |
| Revenue This Year | $10.35 | $39.17 |
| Revenue Next Year | $7.55 | $26.89 |
| P/E Ratio | $33.65 | ★ $16.24 |
| Revenue Growth | 12.20 | ★ 31.19 |
| 52 Week Low | $72.99 | $47.50 |
| 52 Week High | $116.65 | $82.22 |
| Indicator | HQY | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 25.52 | 58.63 |
| Support Level | $77.44 | $71.23 |
| Resistance Level | $80.83 | $82.22 |
| Average True Range (ATR) | 3.16 | 2.48 |
| MACD | -0.58 | 0.38 |
| Stochastic Oscillator | 1.99 | 63.43 |
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.